ELI LILLY & CO (1LLY.MI) Stock Price, Quote, News and Overview
BIT:1LLY - Borsa Italiana Milan - US5324571083 - Common Stock - Currency: EUR
1LLY.MI Quote, Performance and Key Statistics
ELI LILLY & CO
BIT:1LLY (2/4/2025, 7:00:00 PM)
781.6
-8.3 (-1.05%)
The current stock price of 1LLY.MI is 781.6 EUR. In the past month the price increased by 4.19%.
1LLY.MI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 81.81 | 764.20B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.22 | 413.69B | ||
| NOV.DE | NOVO NORDISK A/S-B | 28.95 | 365.11B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.25 | 355.12B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SAN.PA | SANOFI | 14.61 | 257.89B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.1 | 220.08B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B | ||
| PFE.DE | PFIZER INC | 10 | 141.65B |
Related stock screener links
About 1LLY.MI
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. The company is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 43000
Company Website: https://www.lilly.com/
Investor Relations: https://investor.lilly.com/
Phone: 13172762000
1LLY.MI FAQ
What is the stock price of 1LLY.MI?
The current stock price of 1LLY.MI is 781.6 EUR.
What is the symbol for ELI LILLY & CO stock?
The exchange symbol of ELI LILLY & CO is 1LLY and it is listed on the Borsa Italiana Milan exchange.
On which exchange is 1LLY.MI stock listed?
1LLY.MI stock is listed on the Borsa Italiana Milan exchange.
Is 1LLY.MI a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for 1LLY.MI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of 1LLY.MI.
Does 1LLY.MI stock pay dividends?
1LLY.MI has a dividend yield of 0.73%. The yearly dividend amount is currently 4.28.
When does 1LLY.MI stock report earnings?
1LLY.MI will report earnings on 2025-02-06, before the market open.
What is the Price/Earnings (PE) ratio of 1LLY.MI?
The PE ratio for 1LLY.MI is 79.43. This is based on the reported non-GAAP earnings per share of 9.84 and the current share price of 781.6 EUR.
1LLY.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1LLY.MI.
1LLY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. 1LLY.MI has an excellent profitability rating, but there are concerns on its financial health.
1LLY.MI Financial Highlights
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 9.84. The EPS increased by 71.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.48% | ||
| ROA | 11.07% | ||
| ROE | 58.78% | ||
| Debt/Equity | 2.04 |
1LLY.MI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to 1LLY.MI. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 109.18% and a revenue growth 34.67% for 1LLY.MI